Long-Term Outcomes and Prognostic Factors of High-Risk Malignant Melanoma Patients after Surgery and Adjuvant High-Dose Interferon Treatment: A Single-Center Experience

被引：5

作者：

Akman, Tulay ^{[1
]}

Oztop, Ilhan ^{[2
]}

Unek, Ilkay Tugba ^{[2
]}

Koca, Dogan ^{[6
]}

Unal, Olcun Umit ^{[7
]}

Salman, Tarik ^{[4
]}

Yavuzsen, Tugba ^{[2
]}

Yilmaz, Ahmet Ugur ^{[5
]}

Somali, Isil ^{[2
]}

Demir, Necla ^{[2
]}

Ellidokuz, Hulya ^{[3
]}

机构：

[1] Tepecik Educ & Res Hosp, Div Med Oncol, TR-35110 Izmir, Turkey

[2] Dokuz Eylul Univ, Div Med Oncol, Izmir, Turkey

[3] Dokuz Eylul Univ, Div Basic Oncol, Izmir, Turkey

[4] Ataturk Educ & Res Hosp, Div Med Oncol, Izmir, Turkey

[5] Izmir Med Pk Univ, Div Med Oncol, Izmir, Turkey

[6] Istanbul Hosp, Div Med Oncol, Van, Turkey

[7] Ataturk Univ, Div Med Oncol, Erzurum, Turkey

来源：

CHEMOTHERAPY | 2014年 / 60卷 / 04期

关键词：

Interferon; Treatment; Melanoma; Prognostic factors; Survival; Clinicopathological features; AMERICAN JOINT COMMITTEE; COOPERATIVE-ONCOLOGY-GROUP; PRIMARY CUTANEOUS MELANOMA; POOLED ANALYSIS; STAGING SYSTEM; FOLLOW-UP; THERAPY; CANCER; TRIAL; DACARBAZINE;

D O I：

10.1159/000371838

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Surgical excision constitutes an important part of the treatment of local advanced malignant melanoma. Due to the high recurrence risk, adjuvant high-dose interferon therapy is still the only therapy used in stage IIB and III high-risk melanoma patients. Methods: One hundred two high-risk malignant melanoma patients who received high-dose interferon-alpha-2b therapy were evaluated retrospectively. The clinicopathological features, survival times, and prognostic factors of the patients were determined. Results: The median disease-free and overall survival times were 25.2 and 60.8 months, respectively. Our findings revealed that male gender, advanced disease stage, lymph node involvement, lymphatic invasion, the presence of ulceration, and a high Clark level were significant negative prognostic factors. Conclusion: In light of the favorable survival results obtained in this study, high-dose interferon treatment as adjuvant therapy for high-risk melanoma is still an efficient treatment and its possible side effects can be prevented by taking the necessary precautions. (C) 2015 S. Karger AG, Basel

引用

页码：228 / 238

页数：11

共 62 条

[1] Randomized phase III trial of high-dose interferon alfa-2b (HDI) for 4 weeks induction only in patients with intermediate- and high-risk melanoma (Intergroup trial E 1697) [J].

Agarwala, S. S. ;

Lee, S. J. ;

Flaherty, L. E. ;

Smylie, M. ;

Kefford, R. F. ;

Carson, W. E. ;

Cohen, G. ;

Kirkwood, J. M. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

[2]

Agarwala S S, 2000, Forum (Genova), V10, P230

[3]

Albino Anthony P., 1997, P1935

[4]

Algazi Alain P, 2010, Cancer Manag Res, V2, P197, DOI 10.2147/CMR.S6073

[5]

American Cancer Society, 2012, AM CANC SOC CANC TRE

[6]

[Anonymous], Statistics for 2009

[7] Age as a Prognostic Factor in Patients with Localized Melanoma and Regional Metastases [J].

Balch, Charles M. ;

Soong, Seng-Jaw ;

Gershenwald, Jeffrey E. ;

Thompson, John F. ;

Coit, Daniel G. ;

Atkins, Michael B. ;

Ding, Shouluan ;

Cochran, Alistair J. ;

Eggermont, Alexander M. M. ;

Flaherty, Keith T. ;

Gimotty, Phyllis A. ;

Johnson, Timothy M. ;

Kirkwood, John M. ;

Leong, Stanley P. ;

McMasters, Kelly M. ;

Mihm, Martin C., Jr. ;

Morton, Donald L. ;

Ross, Merrick I. ;

Sondak, Vernon K. .

ANNALS OF SURGICAL ONCOLOGY, 2013, 20 (12) :3961-3968

[8] Final Version of 2009 AJCC Melanoma Staging and Classification [J].

Balch, Charles M. ;

Gershenwald, Jeffrey E. ;

Soong, Seng-jaw ;

Thompson, John F. ;

Atkins, Michael B. ;

Byrd, David R. ;

Buzaid, Antonio C. ;

Cochran, Alistair J. ;

Coit, Daniel G. ;

Ding, Shouluan ;

Eggermont, Alexander M. ;

Flaherty, Keith T. ;

Gimotty, Phyllis A. ;

Kirkwood, John M. ;

McMasters, Kelly M. ;

Mihm, Martin C., Jr. ;

Morton, Donald L. ;

Ross, Merrick I. ;

Sober, Arthur J. ;

Sondak, Vernon K. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) :6199-6206

[9] An evidence-based staging system for cutaneous melanoma [J].

Balch, CM ;

Soong, SJ ;

Atkins, MB ;

Buzaid, AC ;

Cascinelli, N ;

Coit, DG ;

Fleming, ID ;

Gershenwald, JE ;

Houghton, A ;

Kirkwood, JM ;

McMasters, KM ;

Mihm, MF ;

Morton, DL ;

Reintgen, DS ;

Ross, MI ;

Sober, A ;

Thompson, JA ;

Thompson, JF .

CA-A CANCER JOURNAL FOR CLINICIANS, 2004, 54 (03) :131-149

[10] Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system [J].

Balch, CM ;

Soong, SJ ;

Gershenwald, JE ;

Thompson, JF ;

Reintgen, DS ;

Cascinelli, N ;

Urist, M ;

McMasters, KM ;

Ross, MI ;

Kirkwood, JM ;

Atkins, MB ;

Thompson, JA ;

Coit, DG ;

Byrd, D ;

Desmond, R ;

Zhang, YT ;

Liu, PY ;

Lyman, GH ;

Morabito, A .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) :3622-3634

← 1 2 3 4 5 6 7 →